Dr. Margaret J. Sampson

Practice Group Co-Chair - IP Transactions (Firmwide) Partner

Margaret Sampson Photo

Austin

P: +1.512.322.2552 F: +1.512.322.3652
  • Represented pharmaceutical company in a world-wide development and collaboration agreement for the development of an implantable drug delivery device for the programmed release of therapeutics to patients, for a $35 million up-front payment in the form of an equity investment and technology access fee
  • Represented pharmaceutical company in its $130 million acquisition, through an unsolicited offer, of a developer of products for the treatment of a central nervous system disorder
  • Represented pharmaceutical company in a world-wide, exclusive license, development and collaboration agreement for the development of an early stage drug product to treat pain for an up-front payment of $41 million, along with additional milestone payments and tiered royalties
  • Represented pharmaceutical company in an exclusive license and supply agreement in the U.S. of an FDA-approved drug product to treat mental disorders for an up-front payment of $40 million, along with additional milestone payments and tiered royalties
  • Represented pharmaceutical company in its acquisition of a privately-held pharmaceutical and drug delivery company focused on inhalation technologies and early stage products for lung diseases and infections, for a $40 million payment, along with additional milestone payments and tiered royalties
  • Represented specialty pharmaceutical company in out-licensing U.S. rights to a post-505(b)(2) filing combination product for the secondary prevention of cardiovascular disease for an up-front payment of $15 million, along with additional milestone payments and tiered royalties
  • Represented biotechnology company in out-licensing ex-U.S. rights to a drug product in Phase 2 clinical trials, as well as in numerous clinical and commercial pharmaceutical product supply agreements, and clinical trial agreements, for the drug product
  • Represented biotechnology company in a joint venture to leverage intellectual property platforms from two companies to develop fusion protein biologics to treat cancer and other human therapeutic indications
  • Represented investment firm in IP due diligence and associated IP licensing and assignment agreements for a $345 million joint venture investment to explore and promote a new technology to produce bio-fuels

Intellectual Property Counseling

  • Represented international investment management company on a royalty purchase agreement for sales of FDA-approved drug in the U.S., which involved managing the interests of multiple parties, including negotiating and drafting ancillary agreements with interested parties
  • Represented a biotechnology company in the development of its licensing strategy for its proprietary pharmaceutical formulation platform technology, and on-going negotiations of transactions with pharmaceutical companies related to such platform technology
  • Represented a biotechnology company in transactions related to the development of the company’s plant-based vaccine expression technology
  • Development of clinical trial agreements for a biotechnology company dedicated to the development, manufacturing, and commercialization of drugs, immunotherapies, tools, and diagnostics primarily in the area of cancer
  • Development of transactional agreements for a biotechnology company dedicated to the long term development of sustainable alternatives for the food, pharmaceuticals, and supplement markets

Patent Litigation

  • (E.D. Tex.) — Represented a pharmaceutical company as a team member in a patent litigation relating to a biologic pharmaceutical product
  • Represented a biotechnology diagnostic company as a team member in a patent litigation and prevailed on summary judgment of non-infringement for proprietary system of stem cell production and sorting
  • (M.D. Tenn.) — Represented a pharmaceutical company as a team member in litigation involving breach of joint development agreement and dispute over patent rights for technology developed as part of the joint development

Patent Post-Grant Proceedings

  • Represented pharmaceutical company in an inter partes review trial before the PTAB regarding a patent covering the company’s marketed drug product; validity of the patent was upheld
  • Represented a research tools company in four inter partes reexaminations related to high-throughput sequencing that resulted in rejections of all challenged patent claims through Actions Closing Prosecution in less than 12 months from filing of initial requests

Arbitration

  • Represented biotechnology company in a dispute with its licensee regarding alleged breach of contract and associated damages to the licensed patent estate; arbitrators awarded damages to biotechnology company
  • Represented a biotechnology research tools company as a team member in an arbitration regarding the client’s cell-based product and prevailed when the U.S. Patent and Trademark Office found that the patent had expired many years earlier